000 01634cam  2200373zi 4500
0019.918775
003CaOODSP
00520230217142033
006m     o  d f      
007cr mn|||||||||
008221230e202302  quca    ob   f000 0 eng d
020 |a9780660469096
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aEn14-509/2023E-PDF
24500|aScreening assessment : |b2H-azepin-2-one, hexahydro- (caprolactam) : Chemical Abstracts Service Registry number 105-60-2.
24617|aScreening assessment - caprolactam
264 1|a[Gatineau, Quebec] : |bGovernment of Canada = Gouvernement du Canada, |cFebruary 2023.
264 4|c©2023
300 |a1 online resource (iv, 27 pages) : |billustrations
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aIssued also in French under title: Évaluation préalable : ε-caprolactame (hexahydro-2H-azépin-2-one) : numéro de registre du Chemical Abstracts Service 105-60-2.
500 |aCover title.
504 |aIncludes bibliographical references.
650 0|aCaprolactam|xEnvironmental aspects|zCanada.
650 0|aCaprolactam|xHealth aspects|zCanada.
650 0|aCaprolactam|xToxicology|zCanada.
650 0|aCaprolactam|xRisk assessment|zCanada.
7101 |aCanada. |bEnvironment and Climate Change Canada, |eissuing body.
7101 |aCanada. |bHealth Canada, |eissuing body.
77508|tÉvaluation préalable : |w(CaOODSP)9.918774
85640|qPDF|s793 KB|uhttps://publications.gc.ca/collections/collection_2023/eccc/En14-509-2023-eng.pdf